Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary roundtable conducted by the FDA in front of its recently-appointed top ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The ...

KJ Muldoon, a 10-month-old baby, was diagnosed with the genetic disease carbamoyl-phosphate synthetase 1 deficiency after he ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Two groundbreaking biotechnology advances are fundamentally altering human health and food production in 2025, moving from ...

Beam Therapeutics (NASDAQ: BEAM) , a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated da ...

G ene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging.

BEAM-101 is an investigational genetically modified ex vivo cell therapy for ... at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable ...

This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD ... certain genetic diseases by targeting and altering specific DNA sequences.

This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD ... certain genetic diseases by targeting and altering specific DNA sequences.

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle ... a DNA sequence in BCL11A ...

Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic therapies for sickle ... multiple DNA base pairs, precisely correcting ...